Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$12.67 USD

12.67
1,561,165

-0.42 (-3.21%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $12.66 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO

by Zacks Equity Research

QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.

Zacks Equity Research

Reasons to Retain Alcon Stock in Your Portfolio for Now

by Zacks Equity Research

Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.

Zacks Equity Research

Zacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGen

by Zacks Equity Research

Bioventus, Great Lakes Dredge & Dock and AxoGen are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

First September Gains in 5 Years? Buy 3 Breakout Stocks Now

by Tirthankar Chakraborty

Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.

Zacks Equity Research

STIM Stock Likely to Gain From Updated TMS Coverage

by Zacks Equity Research

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.

Zacks Equity Research

TNDM Stock Likely to Gain From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.

Zacks Equity Research

EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock

by Zacks Equity Research

When combined with EDAP's Focal One platform, Avenda's Unfold AI enables more accurate and patient-specific treatment options.

Zacks Equity Research

Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aveanna Healthcare (AVAH) and AxoGen (AXGN) have performed compared to their sector so far this year.

Zacks Equity Research

BiomX Stock Gains From Favorable Study Data Presentation on BX004

by Zacks Equity Research

PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.

Zacks Equity Research

Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles

by Zacks Equity Research

Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.

Zacks Equity Research

DGX Stock to Benefit From New Partnership With Sentara Health Plans

by Zacks Equity Research

Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.

Zacks Equity Research

VERO Stock Likely to Get Support From New Regulatory Nod in Australia

by Zacks Equity Research

The latest approval for Venus Concept in Australia reinforces its position as a global player in the aesthetic technology space.

Zacks Equity Research

Abbott Stock Hurt by Macroeconomic Issues & FX Headwind

by Zacks Equity Research

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.

Zacks Equity Research

QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity

by Zacks Equity Research

QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.

Zacks Equity Research

TMO Stock to Gain From Expanded Bioanalytical Services in Sweden

by Zacks Equity Research

Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.

Zacks Equity Research

Reasons to Retain EYE Stock in Your Portfolio for Now

by Zacks Equity Research

The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.

Zacks Equity Research

Is Teleflex Stock a Smart Option for Your Portfolio Right Now?

by Zacks Equity Research

TFX instils optimism with its robust performance in the Interventional category and potential in Asia.

Zacks Equity Research

BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?

by Zacks Equity Research

Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.

Zacks Equity Research

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA

by Zacks Equity Research

Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.

Zacks Equity Research

Should You Continue to Retain MYGN Stock in Your Portfolio?

by Zacks Equity Research

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.

Zacks Equity Research

PEN Stock to Gain From CE Mark Approval for its CAVT Technologies

by Zacks Equity Research

Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.

Zacks Equity Research

IINN Stock Gains on Second US Patent Approval for VORTX System

by Zacks Equity Research

Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.

Zacks Equity Research

PAHC Stock Gains From Innovation, Market Expansion Goal

by Zacks Equity Research

Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.

Zacks Equity Research

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

by Zacks Equity Research

QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.